Glioblastoma Trial Offers Hope with New Ultrasound Tech

A novel clinical trial is showing promising results in treating glioblastoma, a deadly brain cancer. The study utilizes focused ultrasound technology to briefly open the blood-brain barrier, a natural defense that typically prevents medications from reaching the brain. This innovative technique allows chemotherapy drugs to penetrate the brain more effectively.

Becca Valle, a participant in the trial, experienced this treatment after being diagnosed with glioblastoma. She underwent several focused ultrasound sessions over six months, alongside chemotherapy. The treatment, which involves a device worn around the head, has demonstrated early evidence of success, with a significant percentage of patients showing improved survival.

Researchers observed that patients receiving oral chemotherapy combined with focused ultrasound experienced a survival advantage compared to those receiving chemotherapy alone. This suggests the monthly treatment is not only safe but may also enhance tumor control and prolong life. Further research is ongoing to confirm these findings and explore different chemotherapy combinations.

The University of Maryland Medical Center, where the lead researcher Dr. Graeme Woodworth is based, is currently reviewing the focused ultrasound device with the FDA. The hospital is, however, conducting a clinical trial using the technique for brain metastases in lung cancer patients. The research also suggests potential for liquid biopsies to monitor brain cancer progression.

Valle, now 41, is in remission with no evidence of disease four years after her glioblastoma diagnosis, a rare outcome for this aggressive cancer. She credits the trial for her improved prognosis and now focuses on living in the moment, free from the fear of recurrence, highlighting the potential of this therapy to offer a new way forward for glioblastoma patients.